ArticleNature cancer2023

Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors.

Fiore Cattaruzza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.